CEL-SCI Corporation Receives $3 Million from Warrant Exercises

VIENNA, Va.--()--CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, today announced that it has received approximately $3 million through the exercise of warrants by investors to purchase the Company's common stock over the past 45 days. These $3 million are in addition to the $10 million raised in a public offering that closed on April 17, 2014. Proceeds from the warrant exercises and the public offering will be used to fund CEL-SCI’s Phase III head and neck cancer clinical trial, other research and development, and general and administrative expenses.

“The additional funding is helping us execute the clinical development programs for our investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection), both for the global Phase III trial for head and neck cancer and, with the U.S. Navy as a development partner, under a Cooperative Agreement for anal warts in HIV/HPV co-infected men and women," said Geert Kersten, Chief Executive Officer of CEL-SCI.

About CEL-SCI Corporation

CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system. Its lead investigational therapy is Multikine (Leukocyte Interleukin, Injection), currently being studied in a pivotal global Phase III clinical trial. CEL-SCI is also investigating an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized patients and as a vaccine (CEL-2000) for Rheumatoid Arthritis (currently in preclinical testing) using its LEAPS technology platform. The investigational immunotherapy LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu, as CEL-SCI scientists are very concerned about the possible emergence of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

Multikine* is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with its future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

When used in this release, the words "intends," "believes," "anticipated," “plans” and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended September 30, 2013. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Contacts

CEL-SCI Corporation
Gavin de Windt, 703-506-9460

Contacts

CEL-SCI Corporation
Gavin de Windt, 703-506-9460